Cytochrome P450 2D6 (CYP2D6) is a critical pharmacogene involved in the metabolism of~
20% of commonly used drugs across a broad spectrum of medical disciplines including …

Many studies have shown that the efficacy and risk of side effects of drug treatment is
influenced by genetic variants. Evidence based guidelines are essential for implementing …

Background The benefit of pharmacogenetic testing before starting drug therapy has been
well documented for several single gene–drug combinations. However, the clinical utility of …

Translating CYP 2D6 genotype to metabolizer phenotype is not standardized across clinical
laboratories offering pharmacogenetic (PGx) testing and PGx clinical practice guidelines …

Background Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients
and is often the result of reduced activity of the key metabolic enzyme dihydropyrimidine …

Despite advances in the field of pharmacogenetics (PGx), clinical acceptance has remained
limited. The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx …

The field of pharmacogenomics (PGx) is gradually shifting from the reactive testing of single
genes toward the proactive testing of multiple genes to improve treatment outcomes, reduce …

Phenoconversion is the mismatch between the individual's genotype-based prediction of
drug metabolism and the true capacity to metabolize drugs due to nongenetic factors. While …

Importance Evidence of the clinical benefit of pharmacogenetics-informed treatment (PIT)
with antidepressants is still limited. Especially for tricyclic antidepressants (TCAs) …

Many drug–drug interactions (DDI s) are based on alterations of the plasma concentrations
of a victim drug due to another drug causing inhibition and/or induction of the metabolism or …